I, C., GD, K., S, d. P., D, P., F, P., E, A., & S, D. F. (2018). Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life. Dove Medical Press.
Style de citation Chicago (17e éd.)I, Cuomo, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, et De Filippis S. Head-to-head Comparison of 1-year Aripiprazole Long-acting Injectable (LAI) Versus Paliperidone LAI in Comorbid Psychosis and Substance Use Disorder: Impact on Clinical Status, Substance Craving, and Quality of Life. Dove Medical Press, 2018.
Style de citation MLA (8e éd.)I, Cuomo, et al. Head-to-head Comparison of 1-year Aripiprazole Long-acting Injectable (LAI) Versus Paliperidone LAI in Comorbid Psychosis and Substance Use Disorder: Impact on Clinical Status, Substance Craving, and Quality of Life. Dove Medical Press, 2018.